[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fresenius Kabi Taiwan Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100585441","evaluation-of-safety-and-efficacy-of-three-flavors-of-supportan-drink-in-cancer-patients-in-taiwan-100585441",false,"NCT06902402","Evaluation of Safety and Efficacy of Supportan® Drink","Inclusion Criteria:\n\n1\\. Patients receiving chemotherapy and\u002For radiotherapy, or immunotherapy, or targeted therapy;\n\nExclusion Criteria:\n\n1\\. Patient with documented diagnosis of liver, kidney or heart disease in the hospital's electronic medical record (EMR); severity of disease evaluated by Investigator as not being suitable to participate in this study;","ALL","18 Years",{"count":18,"type":19},135,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this clinical trial is to demonstrate safety and efficacy of Supportan® Drink",[25,26],"Cancer","Malnutrition (Calorie)","RECRUITING","2026-09-30",{"date":30,"type":31},"2026-10-01","ACTUAL",{"date":33,"type":31},"2025-04-08",{"date":35,"type":19},"2027-12-31",{"name":37,"class":38},"Fresenius Kabi Taiwan Ltd.","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":20,"phases":48,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":53,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":57,"locationsCount":5},"100584661","suitability-of-two-flavours-of-a-high-energy-low-protein-formula-renalive-lp-in-chronic-kidney-disease-stage-3b-5-outpatients-in-taiwan-100584661","NCT06892249","Suitability of a High-energy, Low-protein Formula (Renalive® LP)","Inclusion Criteria:\n\n(1) Diagnosed with chronic kidney disease stage 3b-5 (with history of eGFR\\\u003C45 mL\u002Fmin\u002F1.73 m2)\n\nExclusion Criteria:\n\n(1) Has received dialysis or are expected to start dialysis within the next 3 months",{"count":47,"type":19},80,[22],"Inclusion criteria (1) Diagnosed with chronic kidney disease stage 3b-5 (with history of eGFR\\\u003C45 mL\u002Fmin\u002F1.73 m2)\n\nExclusion criteria\n\n(1) Has received dialysis or are expected to start dialysis within the next 3 months.",[51,52,26],"CKD","Low Protein Dietary Intake",{"date":30,"type":31},{"date":55,"type":31},"2025-06-04",{"date":35,"type":19},{"name":37,"class":38},""]